Skip to main content

Apellis Pharmaceuticals, Inc.

APLSDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001492422

Apellis Pharmaceuticals, Inc. was delisted in 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Apellis Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Apellis Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Apellis Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Wheeler Craig ADirector0May 14, 20262
Dolsten MikaelDirector0May 14, 20262
Machiels AlecDirector0May 14, 20262
Chan GeraldDirector0May 14, 20262
Watson David O.General Counsel0May 14, 20269
Deschatelets PascalChief Scientific Officer0May 14, 20265
Francois CedricChief Executive Officer0May 14, 20267
Sullivan Timothy EugeneChief Financial Officer0May 14, 20267
O'Brien Stephanie MonaghanDirector0May 14, 20263
Dunlop A. SinclairDirector0May 14, 20264
Fonteyne Paul R.Director0May 14, 20262
Nicholson NurChief Technical Officer0May 14, 20265
Chopas James GeorgeVP/Chief Accounting Officer0May 14, 20265
DeLong Mark JeffreyChief Business & Strat Officer0May 14, 20266
Baumal CarolineChief Medical Officer0May 14, 20265
Walbert KeliDirector0May 14, 20262
Boucher KelleyChief People Officer0May 14, 20262
Meltzer LeslieChief Research and Development0May 14, 20262
Townsend Adam J.Chief Commercial Officer84,050Jan 30, 20250
Lewis KarenChief People Officer70,251Jan 30, 20250
Eisele JeffreyChief Development Officer55,312Jan 30, 20250
Scheibler LukasChief Research Officer68,299Dec 5, 20230
Brown Victoria L.Program Team Lead23,556Jan 24, 20230
Grossi FedericoChief Medical Officer94,884Jan 9, 20230
Morningside Venture Investments Ltd10% Owner12,806,342Nov 18, 20210
Perry Nicole DVice President - Accounting4,847Aug 3, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 11, 2024 (view filing)Mar 83 daysDeschatelets PascalChief Scientific OfficerSSale−69.1K$62.19−$4.30M−5.8%1.12M after3 lots10b5-1
Mar 5, 2024 (view filing)Mar 14 daysFrancois CedricChief Executive OfficerSSale−250.0K$64.12−$16.0M−44.4%313.7K after5 lots10b5-1
Mar 5, 2024 (view filing)Mar 14 daysSullivan Timothy EugeneChief Financial OfficerSSale−6.00K$63.22−$379.3K−6.0%93.3K after2 lots10b5-1
Feb 13, 2024 (view filing)Feb 121 dayWatson David O.General CounselSSale−781$67.77−$52.9K−0.7%103.4K after
Feb 13, 2024 (view filing)Feb 121 dayTownsend Adam J.Chief Commercial OfficerSSale−1.15K$67.77−$77.8K−1.2%92.5K after
Feb 13, 2024 (view filing)Feb 121 daySullivan Timothy EugeneChief Financial OfficerSSale−1.43K$67.77−$97.0K−1.5%93.3K after
Feb 13, 2024 (view filing)Feb 121 dayFrancois CedricChief Executive OfficerSSale−3.96K$67.77−$268.5K−1.2%313.7K after
Feb 13, 2024 (view filing)Feb 121 dayDeschatelets PascalChief Scientific OfficerSSale−1.15K$67.77−$77.8K−0.1%1.12M after
Feb 13, 2024 (view filing)Feb 121 dayDeLong Mark JeffreyChief Business & Strat OfficerSSale−597$67.77−$40.5K−0.9%64.6K after
Jan 31, 2024 (view filing)Jan 292 daysWatson David O.General CounselSSale−906$64.14−$58.1K−0.9%104.2K after
Jan 31, 2024 (view filing)Jan 292 daysTownsend Adam J.Chief Commercial OfficerSSale−906$64.14−$58.1K−1.0%93.6K after
Jan 31, 2024 (view filing)Jan 292 daysSullivan Timothy EugeneChief Financial OfficerSSale−906$64.14−$58.1K−0.9%94.8K after
Jan 31, 2024 (view filing)Jan 292 daysNicholson NurChief Technical OfficerSSale−835$64.14−$53.6K−1.2%67.5K after
Jan 31, 2024 (view filing)Jan 29-302 daysLewis KarenChief People OfficerSSale−1.25K$65.12−$81.4K−2.6%46.4K after2 lots10b5-1
Jan 31, 2024 (view filing)Jan 292 daysFrancois CedricChief Executive OfficerSSale−2.84K$64.14−$182.4K−0.9%317.6K after
Jan 31, 2024 (view filing)Jan 29-302 daysEisele JeffreyChief Development OfficerSSale−1.25K$65.22−$81.5K−2.1%57.2K after2 lots10b5-1
Jan 31, 2024 (view filing)Jan 292 daysDeschatelets PascalChief Scientific OfficerSSale−874$64.14−$56.1K−0.1%1.12M after
Jan 31, 2024 (view filing)Jan 292 daysDeLong Mark JeffreyChief Business & Strat OfficerSSale−367$64.14−$23.5K−0.6%65.2K after
Jan 24, 2024 (view filing)Jan 231 dayLewis KarenChief People OfficerSSale−4.29K$63.69−$273.0K−8.3%47.6K after10b5-1
Jan 24, 2024 (view filing)Jan 231 dayEisele JeffreyChief Development OfficerSSale−7.38K$63.69−$469.9K−11.2%58.5K after10b5-1
Jan 23, 2024 (view filing)Jan 221 dayFrancois CedricChief Executive OfficerSSale−13.4K$65.00−$873.0K−4.0%320.5K after
Jan 23, 2024 (view filing)Jan 221 dayWatson David O.General CounselSSale−4.18K$65.00−$272.0K−3.8%105.1K after
Jan 23, 2024 (view filing)Jan 221 dayTownsend Adam J.Chief Commercial OfficerSSale−3.41K$65.00−$221.8K−3.5%94.5K after
Jan 23, 2024 (view filing)Jan 221 daySullivan Timothy EugeneChief Financial OfficerSSale−3.55K$65.00−$230.8K−3.6%95.7K after
Jan 23, 2024 (view filing)Jan 221 dayNicholson NurChief Technical OfficerSSale−2.59K$65.00−$168.5K−3.7%68.3K after
Jan 23, 2024 (view filing)Jan 221 dayLewis KarenChief People OfficerSSale−1.74K$65.00−$113.0K−3.2%51.9K after
Jan 23, 2024 (view filing)Jan 221 dayEisele JeffreyChief Development OfficerSSale−1.61K$65.00−$104.5K−2.4%65.8K after
Jan 23, 2024 (view filing)Jan 221 dayDeschatelets PascalChief Scientific OfficerSSale−3.91K$65.00−$254.3K−0.3%1.12M after
Jan 23, 2024 (view filing)Jan 221 dayDeLong Mark JeffreyChief Business & Strat OfficerSSale−1.38K$65.00−$90.0K−2.1%65.6K after
Jan 23, 2024 (view filing)Jan 221 dayChopas James GeorgeVP/Chief Accounting OfficerSSale−1.06K$65.00−$69.0K−2.6%39.1K after
Jan 18, 2024 (view filing)Jan 171 dayEisele JeffreyChief Development OfficerSSale−5.21K$65.58−$341.5K−7.2%67.4K after10b5-1
Jan 18, 2024 (view filing)Jan 171 dayLewis KarenChief People OfficerSSale−3.28K$65.58−$214.8K−5.8%53.7K after10b5-1
Jan 17, 2024 (view filing)Jan 161 dayDeschatelets PascalChief Scientific OfficerSSale−1.63K$66.81−$109.0K−0.1%1.12M after
Jan 17, 2024 (view filing)Jan 161 dayChopas James GeorgeVP/Chief Accounting OfficerSSale−864$66.81−$57.7K−2.1%40.1K after
Jan 17, 2024 (view filing)Jan 161 dayLewis KarenChief People OfficerSSale−1.63K$66.81−$109.0K−2.8%56.9K after
Jan 17, 2024 (view filing)Jan 161 dayDeLong Mark JeffreyChief Business & Strat OfficerSSale−1.63K$66.81−$109.0K−2.4%67.0K after
Jan 17, 2024 (view filing)Jan 161 dayNicholson NurChief Technical OfficerSSale−1.86K$66.81−$124.1K−2.6%70.9K after
Jan 17, 2024 (view filing)Jan 161 dayWatson David O.General CounselSSale−4.24K$66.81−$283.3K−3.7%109.3K after
Jan 17, 2024 (view filing)Jan 161 dayTownsend Adam J.Chief Commercial OfficerSSale−2.23K$66.81−$149.3K−2.2%97.9K after
Jan 17, 2024 (view filing)Jan 161 daySullivan Timothy EugeneChief Financial OfficerSSale−2.23K$66.81−$149.3K−2.2%99.2K after
Jan 17, 2024 (view filing)Jan 161 dayFrancois CedricChief Executive OfficerSSale−7.85K$66.81−$524.5K−2.3%333.9K after
Jan 17, 2024 (view filing)Jan 161 dayEisele JeffreyChief Development OfficerSSale−438$66.81−$29.3K−0.6%72.7K after
Jan 5, 2024 (view filing)Jan 41 dayBaumal CarolineChief Medical OfficerSSale−2.75K$60.05−$165.2K−7.7%32.9K after
Dec 28, 2023 (view filing)Dec 26-272 daysEisele JeffreyChief Development OfficerSSale−303$59.70−$18.1K−0.6%53.6K after2 lots10b5-1
Dec 20, 2023 (view filing)Dec 191 dayWatson David O.General CounselSSale−3.90K$57.22−$223.5K−4.2%89.8K after2 lots
Dec 5, 2023 (view filing)Dec 14 daysScheibler LukasChief Research OfficerSSale−10.0K$60.00−$600.0K−12.8%68.3K after10b5-1
Dec 5, 2023 (view filing)Dec 14 daysTownsend Adam J.Chief Commercial OfficerSSale−110.0K$60.81−$6.69M−59.0%76.4K after2 lots10b5-1
Dec 5, 2023 (view filing)Dec 14 daysDunlop A. SinclairDirectorSSale−24.0K$61.14−$1.47M−11.1%192.7K after
Dec 1, 2023 (view filing)Nov 301 daySullivan Timothy EugeneChief Financial OfficerSSale−14.2K$54.73−$774.9K−15.4%77.7K after2 lots10b5-1
Nov 21, 2023 (view filing)Nov 174 daysDunlop A. SinclairDirectorSSale−8.89K$49.99−$444.6K−6.8%122.4K after